The Asia Pacific Narcolepsy Drugs Market was worth USD XX million in 2018 and estimated to be growing at a CAGR of XX%, to reach USD XX million by 2023. Narcolepsy is a neurological disorder that decreases the ability to regulate sleep cycles.
It is a long term neurological disorder that includes periods of excessive daytime sleepiness that last from seconds to minutes and can occur at any time. Sometimes these sessions can cause sudden loss of muscle loss that is termed as cataplexy, and occurs in 70% of the cases. Currently there is no cure but lifestyle changes and medications help in developing tolerance to the disorder.
Factors accountable for the growth of market are increasing number of individuals affected by this conditions and increasing severity of the diseases, favourable reimbursement policies and increasing awareness regarding the medications available to treat the disorder. On the other hand, expensive manufacturing costs and strict regulations are the factors hindering the market.
The Asia Pacific market for Narcolepsy Drugs is segmented based on Type and Indication. Based on Type it is divided into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others. Based on Indications it is divided into Daytime Extreme Sleepiness, Cataplexia and Others. Based on geographical analysis, the market is divided into regions of China, India, Japan, South Korea and Australia. China holds the major share in the market due to presence of market leaders as well as the presence of a stellar healthcare system. India is the fastest growing region due to increasing disposable income, growing awareness and increasing adoption rate.
Some of the key players dominating this market include Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Central Nervous System Stimulants
5.1.3 Tricyclic Antidepressants
5.1.4 Sodium Oxybate
5.1.5 Selective Serotonin Reuptake Inhibitor
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Type
5.1.8 Market Attractiveness Analysis, By Type
5.1.9 Market Share Analysis, By Type
5.2 Indication
5.2.1 Introduction
5.2.2 Daytime Extreme Sleepiness
5.2.3 Cataplexia
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Indication
5.2.6 Market Attractiveness Analysis, By Indication
5.2.7 Market Share Analysis, By Indication
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Indication
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Ligand Pharmaceuticals
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Addrenex Pharmaceuticals
8.3 Shire Plc
8.4 Teva Pharmaceutical Industries Ltd.
8.5 Arena Pharmaceuticals
8.6 Jazz Pharmaceuticals Plc
8.7 Bioprojet
8.8 Graymark Healthcare, Inc
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
